Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comparison Study Of Lucentis, Avastin And Eylea In DME Starts With NIH Funding

This article was originally published in The Pink Sheet Daily

Executive Summary

The study’s sponsor, the NIH-funded Diabetic Retinopathy Clinical Research Network, highlighted the cost disparity between treatments for diabetic macular edema in a summary of the study’s purpose.


Related Content

Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Genentech Says Lucentis DME Product Will Ship Shortly
Avastin Safety Questions In Wet AMD Linger With Two-Year CATT Results
Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts